Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Corcept Therapeutics (CORT – Research Report) on January 2. The company’s shares closed yesterday at $25.34.
Ruiz covers the Healthcare sector, focusing on stocks such as Lantheus, Cytokinetics, and Vir Biotechnology. According to TipRanks, Ruiz has an average return of -19.3% and a 31.07% success rate on recommended stocks.
Corcept Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $37.40.
See the top stocks recommended by analysts >>
Based on Corcept Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $117.72 million and a net profit of $27.53 million. In comparison, last year the company earned a revenue of $103.39 million and had a net profit of $27.41 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corcept Therapeutics (CORT) Company Description:
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
Read More on CORT:
- Corcept Therapeutics price target lowered to $28 from $34 at H.C. Wainwright
- Piper still constructive on Corcept despite patent case ‘disappointing’ outcome
- Corcept Therapeutics says court finds patents not infringed
- Corcept selloff today ‘ideal buying opportunity,’ says Canaccord
- Corcept sinks after judge rules for Teva in Korlym patent case
